Jade Biosciences任命Mark Eisner醫學博士為董事會成員

EX-99.1
2
d127137dex991.htm
EX-99.1

EX-99.1

 

 Exhibit 99.1 

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors 

San Francisco and Vancouver, British Columbia, June 26, 2026 — Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a
clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H.,
to its Board of Directors, effective June 25, 2026. 
 “We are pleased to welcome Dr. Eisner to the board,” said Tom Frohlich, Chief
Executive Officer of Jade Biosciences. “Mark’s biopharmaceutical executive experience and proven track record guiding innovative therapies from early clinical development through regulatory approval and global commercialization will be
highly valuable as Jade rapidly advances its pipeline of antibody-based therapies for autoimmune diseases.” 
 Dr. Mark Eisner, M.D., M.P.H., has
more than 25 years of leadership in clinical development and immunology. He most recently served as Executive Vice President and Chief Medical Officer of Vir Biotechnology, where he oversaw clinical development, regulatory sciences, and medical
affairs. Previously, he served as Chief Medical Officer at Sonoma Biotherapeutics and FibroGen, and spent nearly 11 years at Genentech/Roche, including as Senior Vice President and Global Head of Product Development for Immunology, Infectious
Disease, and Ophthalmology. In that role, he led multinational development programs and global regulatory submissions across major therapeutic areas. Prior to entering industry, Dr. Eisner was Professor of Medicine and Anesthesia at
the University of California, San Francisco. 
 “I am excited to join the Board of Directors at Jade as the Company rapidly advances its
portfolio of potential best-in-class therapies for multiple autoimmune diseases,” said Dr. Eisner. “Jade is well-positioned to address areas of
substantial unmet need for patients, and I look forward to contributing as a board member to support the impact.” 
 About Jade Biosciences, Inc.

 Jade Biosciences is a clinical-stage biotechnology company focused on developing
best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently
being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody
program. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn. 

Forward-Looking Statements 
 Certain statements in this
communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private
Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its
pipeline and business including, without limitation, the potential of Jade’s product candidates to become best-in-class therapies and their potential therapeutic
uses. The words “opportunity,” “potential,” “milestones,” 

 

 
“pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,”
“will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have
been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those
expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that ongoing and any future clinical trials may not demonstrate desirable efficacy or clinical profiles; adverse
events and safety signals may occur; Jade’s product candidates may fail in development, may not receive required regulatory approvals, or may be delayed; enrollment or regulatory challenges may occur; and the other risks, uncertainties and
factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026). Should one
or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue
reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release
publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. 

Jade Biosciences Contact 
 Priyanka Shah 

[email protected] 
 [email protected] 

908-447-6134 

 

  
 Page 2